1306 related articles for article (PubMed ID: 25819854)
1. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
[TBL] [Abstract][Full Text] [Related]
3. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
4. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
[TBL] [Abstract][Full Text] [Related]
5. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
[TBL] [Abstract][Full Text] [Related]
6. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
Schneider PA; Laird JR; Tepe G; Brodmann M; Zeller T; Scheinert D; Metzger C; Micari A; Sachar R; Jaff MR; Wang H; Hasenbank MS; Krishnan P;
Circ Cardiovasc Interv; 2018 Jan; 11(1):e005891. PubMed ID: 29326153
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
8. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Rosenfield K; Jaff MR; White CJ; Rocha-Singh K; Mena-Hurtado C; Metzger DC; Brodmann M; Pilger E; Zeller T; Krishnan P; Gammon R; Müller-Hülsbeck S; Nehler MR; Benenati JF; Scheinert D;
N Engl J Med; 2015 Jul; 373(2):145-53. PubMed ID: 26106946
[TBL] [Abstract][Full Text] [Related]
9. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
[TBL] [Abstract][Full Text] [Related]
10. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
Scheinert D; Duda S; Zeller T; Krankenberg H; Ricke J; Bosiers M; Tepe G; Naisbitt S; Rosenfield K
JACC Cardiovasc Interv; 2014 Jan; 7(1):10-9. PubMed ID: 24456716
[TBL] [Abstract][Full Text] [Related]
11. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial.
Tepe G; Laird J; Schneider P; Brodmann M; Krishnan P; Micari A; Metzger C; Scheinert D; Zeller T; Cohen DJ; Snead DB; Alexander B; Landini M; Jaff MR;
Circulation; 2015 Feb; 131(5):495-502. PubMed ID: 25472980
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
Laird JA; Schneider PA; Jaff MR; Brodmann M; Zeller T; Metzger DC; Krishnan P; Scheinert D; Micari A; Wang H; Masters M; Tepe G
Circ Cardiovasc Interv; 2019 Jun; 12(6):e007702. PubMed ID: 31195825
[TBL] [Abstract][Full Text] [Related]
13. Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents?
Antoniou GA; Georgakarakos EI; Antoniou SA; Georgiadis GS
Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):282-5. PubMed ID: 24729201
[TBL] [Abstract][Full Text] [Related]
14. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
Laird JR; Schneider PA; Tepe G; Brodmann M; Zeller T; Metzger C; Krishnan P; Scheinert D; Micari A; Cohen DJ; Wang H; Hasenbank MS; Jaff MR;
J Am Coll Cardiol; 2015 Dec; 66(21):2329-2338. PubMed ID: 26476467
[TBL] [Abstract][Full Text] [Related]
15. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
[TBL] [Abstract][Full Text] [Related]
16. 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty.
Marmagkiolis K; Hakeem A; Choksi N; Al-Hawwas M; Edupuganti MM; Leesar MA; Cilingiroglu M
Catheter Cardiovasc Interv; 2014 Oct; 84(4):555-64. PubMed ID: 24740749
[TBL] [Abstract][Full Text] [Related]
17. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study).
Shishehbor MH; Zeller T; Werner M; Brodmann M; Parise H; Holden A; Lichtenberg M; Parikh SA; Kashyap VS; Pietras C; Tirziu D; Ardakani S; Beschorner U; Krishnan P; Niazi KA; Wali AU; Lansky AJ
Circulation; 2022 May; 145(22):1645-1654. PubMed ID: 35377157
[TBL] [Abstract][Full Text] [Related]
18. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.
Bausback Y; Wittig T; Schmidt A; Zeller T; Bosiers M; Peeters P; Brucks S; Lottes AE; Scheinert D; Steiner S
J Am Coll Cardiol; 2019 Feb; 73(6):667-679. PubMed ID: 30765033
[TBL] [Abstract][Full Text] [Related]
19. Drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial.
Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
Catheter Cardiovasc Interv; 2019 Mar; 93(4):664-672. PubMed ID: 30747489
[TBL] [Abstract][Full Text] [Related]
20. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial.
Zeller T; Baumgartner I; Scheinert D; Brodmann M; Bosiers M; Micari A; Peeters P; Vermassen F; Landini M; Snead DB; Kent KC; Rocha-Singh KJ;
J Am Coll Cardiol; 2014 Oct; 64(15):1568-76. PubMed ID: 25301459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
